AU2014229502B2 - Compositions and Methods for Enhancing the Therapeutic Potential of Stem Cells - Google Patents

Compositions and Methods for Enhancing the Therapeutic Potential of Stem Cells Download PDF

Info

Publication number
AU2014229502B2
AU2014229502B2 AU2014229502A AU2014229502A AU2014229502B2 AU 2014229502 B2 AU2014229502 B2 AU 2014229502B2 AU 2014229502 A AU2014229502 A AU 2014229502A AU 2014229502 A AU2014229502 A AU 2014229502A AU 2014229502 B2 AU2014229502 B2 AU 2014229502B2
Authority
AU
Australia
Prior art keywords
disease
cells
stem cells
pad
mscs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014229502A
Other languages
English (en)
Other versions
AU2014229502A9 (en
AU2014229502A1 (en
Inventor
Barbara Reinisch
Claudia Rosenbaum
Judith Schenk
Christian Van Den Bos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2014229502A1 publication Critical patent/AU2014229502A1/en
Publication of AU2014229502A9 publication Critical patent/AU2014229502A9/en
Assigned to VAN DEN BOS, CHRISTIAN reassignment VAN DEN BOS, CHRISTIAN Request for Assignment Assignors: LONZA COLOGNE GMBH
Application granted granted Critical
Publication of AU2014229502B2 publication Critical patent/AU2014229502B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
AU2014229502A 2013-03-15 2014-03-13 Compositions and Methods for Enhancing the Therapeutic Potential of Stem Cells Active AU2014229502B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159548.0A EP2777703B1 (en) 2013-03-15 2013-03-15 Compositions and methods for enhancing the therapeutic potential of stem cells
EP13159548.0 2013-03-15
PCT/IB2014/001248 WO2014140930A2 (en) 2013-03-15 2014-03-13 Compostions and methods for enhancing the therapeutic potential of stem cells

Publications (3)

Publication Number Publication Date
AU2014229502A1 AU2014229502A1 (en) 2015-09-24
AU2014229502A9 AU2014229502A9 (en) 2016-06-16
AU2014229502B2 true AU2014229502B2 (en) 2019-03-14

Family

ID=47900872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014229502A Active AU2014229502B2 (en) 2013-03-15 2014-03-13 Compositions and Methods for Enhancing the Therapeutic Potential of Stem Cells

Country Status (10)

Country Link
US (4) US20160030482A1 (enExample)
EP (1) EP2777703B1 (enExample)
JP (1) JP6399410B2 (enExample)
KR (1) KR102203925B1 (enExample)
CN (1) CN105050597A (enExample)
AU (1) AU2014229502B2 (enExample)
BR (1) BR112015022565A2 (enExample)
CA (1) CA2905650C (enExample)
ES (1) ES2602078T3 (enExample)
WO (1) WO2014140930A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111405898B (zh) * 2018-01-29 2022-09-13 中国科学院动物研究所 一种破坏细胞机械稳态以及促进组织器官的再生修复的方法及其应用
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CN108728410B (zh) * 2018-06-19 2020-04-21 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法
JP7230409B2 (ja) * 2018-10-02 2023-03-01 カシオ計算機株式会社 判定装置、判定方法及び判定プログラム
KR102932345B1 (ko) 2019-03-08 2026-02-27 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 식물 세포에서 니트로게나제 폴리펩티드의 발현

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216181A1 (en) * 2009-02-20 2010-08-26 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
US20120058561A1 (en) * 2009-04-13 2012-03-08 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2012062819A2 (en) * 2010-11-09 2012-05-18 Lonza Cologne Gmbh Method for controlling binding of cells to a substrate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011176A2 (en) 2006-07-21 2008-01-24 Northwestern University Myosin light chain kinase inhibitor compounds, compositions and related methods of use
CN101125146B (zh) * 2007-07-02 2011-05-04 中国药科大学 一种防治炎症相关心脑血管疾病的药物靶标及其抑制剂
AU2009208391A1 (en) * 2008-01-31 2009-08-06 Monash University Methods of treating thromboembolic disorders
CN102940631B (zh) * 2012-11-02 2015-04-15 清华大学 Blebbistatin在促进干细胞存活和维持干细胞干性中的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216181A1 (en) * 2009-02-20 2010-08-26 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
US20120058561A1 (en) * 2009-04-13 2012-03-08 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2012062819A2 (en) * 2010-11-09 2012-05-18 Lonza Cologne Gmbh Method for controlling binding of cells to a substrate

Also Published As

Publication number Publication date
JP6399410B2 (ja) 2018-10-03
US20200147142A1 (en) 2020-05-14
WO2014140930A2 (en) 2014-09-18
EP2777703A1 (en) 2014-09-17
CA2905650C (en) 2022-08-23
KR102203925B1 (ko) 2021-01-19
US20240316111A1 (en) 2024-09-26
US20160030482A1 (en) 2016-02-04
AU2014229502A9 (en) 2016-06-16
WO2014140930A9 (en) 2016-01-14
JP2016510808A (ja) 2016-04-11
CA2905650A1 (en) 2014-09-18
ES2602078T3 (es) 2017-02-17
CN105050597A (zh) 2015-11-11
EP2777703B1 (en) 2016-09-14
BR112015022565A2 (pt) 2017-07-18
WO2014140930A3 (en) 2014-12-24
AU2014229502A1 (en) 2015-09-24
KR20150131324A (ko) 2015-11-24
US20180055888A1 (en) 2018-03-01

Similar Documents

Publication Publication Date Title
US20240316111A1 (en) Compositions and methods for enhancing the therapeutic potential of stem cells
US10639335B2 (en) Pluripotent stem cell that induces repair and regeneration after myocardial infarction
US12076340B2 (en) Use of trientine to deliver copper to ischemic tissue
JP5340941B2 (ja) 血液、特に末梢血から成体幹細胞を増殖させるための方法及び医療分野におけるその利用
JP2010504083A5 (enExample)
JP2012516853A (ja) 分化した内皮前駆細胞の治療的使用
AU2019418187C1 (en) Novel glia-like cells differentiated from somatic cells, preparation method therefor, cocktail composition for preparing same, cell therapeutic agent for preventing or treating neurological disorders, comprising same, and method for preventing and treating neurological disorders by administering same
JP2021155335A (ja) 変形性関節症の処置および／または予防方法
Parra et al. Autologous platelet concentrates as treatment for avascular necrosis of femoral head in a dog
Leong et al. Effects of adipose-derived mesenchymal stem cells in two Poodle dogs with pulmonary hypertension secondary to myxomatous mitral valve disease
WO2024048652A1 (ja) 骨および／または軟骨再生用の組成物、骨および／または軟骨の疾患の処置および／または予防用の組成物
HK1261492B (en) Use of trientine to deliver copper to ischemic tissue

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS

SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: VAN DEN BOS, CHRISTIAN

Free format text: FORMER APPLICANT(S): LONZA COLOGNE GMBH

FGA Letters patent sealed or granted (standard patent)